UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
SLXN holding history
Silexion Therapeutics Corp in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
SLXN overviewAll 13F holders of SLXNFull Q2 2026 holdings
- Shares (Q2 2026)
- 1,411
- Value
- $3.60K
- % of portfolio
- <0.1%
- Quarters held
- 8
- Since Q3 2024
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,411 | $3.60K | <0.1% | +894+172.9% | Added | Holders |
| Q1 2026 | 517 | $662 | <0.1% | −1,174−69.4% | Reduced | Holders |
| Q4 2025 | 1,691 | $3.25K | <0.1% | +999+144.4% | Added | Holders |
| Q3 2025 | 692 | $2.35K | <0.1% | −108,565−99.4% | Reduced | Holders |
| Q2 2025 | 109,257 | $88.5K | <0.1% | +36,383+49.9% | Added | Holders |
| Q1 2025 | 72,874 | $80.2K | <0.1% | +58,020+390.6% | Added | Holders |
| Q4 2024 | 14,854 | $29.9K | <0.1% | −205−1.4% | Reduced | Holders |
| Q3 2024 | 15,059 | $7.91K | <0.1% | +15,059 | New | Holders |